SecBot SecBot
Insider Cluster (13 insiders) ·Filed Aug 12, 2026

TAK

TAKEDA PHARMACEUTICAL CO LTD
NEUTRAL
Impact 3/10
Horizondays Processed3mo ago
Insider cluster: 13 insiders, $8.6M total
Actionable Insight • Neutral

The cluster is too small relative to market cap to be a standalone signal. Monitor for any upcoming earnings or pipeline catalysts that might have prompted the selling, but no immediate action is warranted.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$17.39
T+0 close · Aug 12, 2026 · via day close
Latest settled
+20.87%
T+60 · $21.02
Vs SPY
+26.35%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 13 $17.39entry
  2. T+1 · 3mo ago +1.38%α +1.58% · $17.63
  3. T+5 · 3mo ago +4.26%α +6.22% · $18.13
  4. T+20 · 2mo ago +5.00%α +6.75% · $18.26
  5. T+60 · 11d ago +20.87%α +26.35% · $21.02
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

A cluster of 13 Takeda insiders, including the CEO and President of R&D, sold a total of $8.64M in open-market sales on August 10, 2026. While the dollar amount is only ~0.016% of the $55.2B market cap (trivial), the breadth of the selling, covering the CEO, C-suite, and multiple business unit presidents on a single day, is notable. Per the academic literature, cluster sells are weak predictors, and the proportionality is below the materiality threshold, making this a neutral event with low impact.

Key Financial Metrics

Direction
selling
Total Value
$8.6M
Insiders
13

Key Facts

  • 13 insiders sold shares on August 10, 2026, totaling $8.64M.
  • CEO Julie So-Young Kim sold $1.52M; President of R&D Andrew Plump sold $2.83M.
  • Total sales represent ~0.016% of Takeda's $55.2B market cap.
  • No insider purchases were reported in the cluster window.

Financial Impact

$8.64M in insider sales, trivial relative to $55.2B market cap

dilution

Risk Factors

  • Insider selling could indicate a lack of confidence in near-term prospects, though the dollar amount is immaterial.
  • No purchases to offset the selling signal.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-TAK-1786611740779

Track record

18 reports on TAK

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $21.19 to $21.12 Now $21.59 +1.89% ▼ −0.33% −3.62% vs SPY
  2. Oct 30, 202617d ago 144 Neutral 2/10 Entry $20.87 to $21.09 Now $21.59 +3.45% ▲ +1.05% +0.98% vs SPY
  3. Oct 30, 202617d ago 144 Neutral 2/10 Entry $20.87 to $21.09 Now $21.59 +3.45% ▲ +1.05% +0.98% vs SPY
  4. Oct 29, 202618d ago 6-K Neutral 4/10 No price data
  5. Oct 29, 202618d ago 6-K Bearish 5/10 Entry $20.01 to $21.19 Now $21.59 −7.90% ▼ −5.90% −10.62% vs SPY
  6. Sep 14, 20269w ago 6-K Bullish 7/10 Entry $18.60 to $18.89 Now $21.59 +16.08% ▲ +1.56% +1.45% vs SPY
  7. Aug 21, 202612w ago Insider Cluster Neutral 2/10 Entry $18.24 to $17.98 Now $21.59 +18.37% ▼ −1.43% −1.89% vs SPY
  8. Aug 19, 202612w ago Insider Cluster Neutral 2/10 Entry $18.13 to $18.03 Now $21.59 +19.08% ▼ −0.55% −1.67% vs SPY
  9. Aug 14, 202613w ago Court Ruling Neutral 4/10 Entry $17.38 to $18.24 Now $21.59 +24.22% ▲ +4.95% +6.14% vs SPY
  10. Aug 12, 202613w ago Insider Cluster Neutral 3/10 Viewing Entry $17.39 to $18.13 Now $21.59 +24.15% ▲ +4.26% +6.22% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens Wed (11h 3m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 13, 2026